


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (currently amended): A compound of the formula



wherein

R¹ represents a hydrogen atom or a group selected from the formulae (A) and (B)

(A) R³-CO-(CH₂)_s-CO-,

in which

R³ represents R⁴-Z¹ with Z¹ being O or NR⁵, R⁴, R⁵ being each independently hydrogen or C₁₋₆ alkyl, and

s is an integer from 1 to 4;

(B) R⁶-CO-

in which

R⁶ represents a C₁₋₆ alkyl group, a C₁₋₆ haloalkyl group or a phenyl group being optionally substituted by one or more substituents selected from the group consisting of halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, amino, C₁₋₆ alkylamino, di-(C₁₋₆ alkyl)-amino, C₁₋₆ alkoxycarbonyl, formyl, carboxy, hydroxy, cyano, SO₃H and nitro;

Xaa¹ each independently represent an amino acid or the N-alkylated derivative thereof, at least one of which being N-terminally linked to R¹;

n is 0 or an integer from 1 to 3;

Y represents a single bond, or if t is 0, a spacer group selected from -O- and -NH-;

R² represents a hydroxy group or a group of formula (C)

(C) -Z²-R⁷

in which

Z^2 represents O or NR^8 ,

R^7 represents

- (a) a C_{1-6} alkyl group being optionally substituted by one or more substituents selected from the group consisting of halogen, C_{3-8} -cycloalkyl, phenyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, amino, C_{1-6} alkylamino, di- $(C_{1-6}$ alkyl)-amino, C_{1-6} alkoxycarbonyl, formyl, carboxy, hydroxy, cyano and nitro, or
- (b) a phenyl group being optionally substituted by one or more substituents selected from the group consisting of halogen, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, amino, C_{1-6} alkylamino, di- $(C_{1-6}$ alkyl)-amino, C_{1-6} alkanoylamino, C_{1-6} alkoxycarbonyl, formyl, carboxy, hydroxy, cyano and nitro,

R^8 represents a hydrogen atom or C_{1-6} alkyl group;

Xaa^2 each independently represent an amino acid or the N-alkylated derivative thereof, in which the amino group of the N-terminally amino acid may have been replaced by Y, and one of which being C-terminally linked to R^2 ;

t is 0 or an integer from 1 to 3;

X is selected from ethyl, thiomethyl and C_3 - C_8 -cycloalkyl; and

m is 1 or 2,

or a pharmaceutically acceptable salt or solvate thereof.

Claim 2 (original): A compound according to claim 1, wherein

Xaa^1 each independently is selected from the group of amino acids consisting of: Leu, Ile, Nva, Abu, Glu, Tle, Phg, Val, allo-Ile, Cpa, Met, Thr, Chg, S-Methylcystein, D-Leu, Nip, CBA (Cyanobutyric acid) and Allyl-Glycin; and
n is 1 or 2.

Claim 3 (original): A compound according to claim 1, wherein




Xaa^2 each independently is selected from the group of amino acids consisting of: Val, Ala, Leu, Ile, Nva, Abu, Cha, Tle, Phg, Glu, Nle, Phe, His, Ser, Cpa, and Asp; and
s is 1 or 2.


Claim 4 (original): A compound according to claim 2, wherein

Xaa² each independently is selected from the group of amino acids consisting of: Val, Ala, Leu, Ile, Nva, Abu, Cha, Tle, Phg, Glu, Nle, Phe, His, Ser, Cpa, and Asp; and s is 1 or 2.

Claim 5 (original): A compound according to claim 1, wherein m represents 1.

Claim 6 (original): A compound selected from the formulae (IA) through (ID):





in which R^1 , R^2 , Xaa^1 , Xaa^2 , n and t are as defined in claim 1, and
 X represents ethyl, thiomethyl or cyclopropyl; or a pharmaceutically acceptable salt or solvate thereof.

Claim 7 (original): A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable salt or solvate thereof; and a pharmaceutically acceptable carrier or diluent.

Claim 8 (original): A pharmaceutical composition comprising a compound according to claim 6 or a pharmaceutically acceptable salt or solvate thereof; and a pharmaceutically acceptable carrier or diluent.

Claim 9 (original): A pharmaceutical composition according to claim 7, which further comprises an active ingredient selected from the group consisting of: atorvastatin, besipirdine, cevimeline, donepezil, eptastigmine, galantamine, glatiramer acetate, icopezil, ipidacrine, lazabemide, linopirdine, lubeluzole, memantine, metrifonate, milameline, nefiracetam, nimodipine, octreotide, rasagiline, rivastigmine, sabcomeline, sabeluzole, tacrine, valproate sodium, velnacrine, YM 796, Phenserine and zanapezil.

Claim 10 (currently amended): A pharmaceutical composition according to claim 7, which further comprises an antiinflammatory agent selected from the group consisting of: rofecoxib, celecoxib, valdecoxib, nitroflurbiprofen, IQ-201, NCX-2216, CPI-1189, a complex of proline-rich polypeptides derived from ovine colostrums and sold under the trademark Colostrinin, ibuprofen, indomethacin, meloxicam, and sulindac sulphide.

Application No. 10/840,037
Amdt dated January 9, 2006
Reply to Office action of August 23, 2005

Claim 11 (currently amended) A pharmaceutical composition according to claim 9, which further comprises an antiinflammatory agent selected from the group consisting of: rofecoxib, celecoxib, valdecoxib, nitroflurbiprofen, IQ-201, NCX-2216, CPI-1189, a complex of proline-rich polypeptides derived from ovine colostrums and sold under the trademark Colostrinin, ibuprofen, indomethacin, meloxicam, and sulindac sulphide.

Claim 12 (original): A pharmaceutical composition according to claim 7, which further comprises a nerve growth factor or a nerve growth modulator selected from the group consisting of: ABS-205, Inosine, KP-447, letepirim, MCC-257, NS-521, and xaliproden.

Claim 13 (original): A pharmaceutical composition according to claim 9, which further comprises a nerve growth factor or a nerve growth modulator selected from the group consisting of: ABS-205, Inosine, KP-447, letepirim, MCC-257, NS-521, and xaliproden.

Claim 14 (original): A pharmaceutical composition according to claim 11, which further comprises a nerve growth factor or nerve growth modulator selected from the group consisting of: ABS-205, Inosine, KP-447, letepirim, MCC-257, NS-521, and xaliproden.

Claims 15-18 (canceled)